Patent: 9,995,752
✉ Email this page to a colleague
Summary for Patent: 9,995,752
Title: | Methods and compositions for determining and treating relapse in inflammatory bowel disease |
Abstract: | Described are methods and compositions for evaluating the relapse risk n subjects having an inflammatory bowel disease (IBD). Some embodiments include selecting a treatment for an evaluated IBD relapse risk in a subject. |
Inventor(s): | Denson; Lee A. (Wyoming, OH), Trapnell; Bruce C. (Liberty Township, OH), Dabritz; Jan (Berlin, DE) |
Assignee: | Children\'s Hospital Medical Center (Cincinnati, OH) Westfaelische Wilhelms-Universitaet Muenster (Muenster, DE) |
Application Number: | 14/890,257 |
Patent Claims: | see list of patent claims |
Details for Patent 9,995,752
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2033-05-14 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 12/31/2002 | ⤷ Try a Trial | 2033-05-14 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 02/21/2008 | ⤷ Try a Trial | 2033-05-14 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |